Prime Highlights-
- Sun Pharmaceutical Industries will acquire US-based Organon in an all-cash deal worth $11.75 billion, marking one of the biggest overseas acquisitions by an Indian pharmaceutical company.
- The acquisition will expand Sun Pharma’s global presence and strengthen its position in high-growth segments such as biosimilars and women’s health.
Key Facts-
- Sun Pharma will acquire all outstanding shares of Organon for $14 per share in cash, with the deal expected to close in the first quarter of 2027, subject to regulatory and shareholder approvals.
- Organon’s portfolio includes women’s health, biosimilars and established medicines, with products sold in more than 140 countries.
Background-
Sun Pharmaceutical Industries is set to acquire US-based healthcare company Organon in an all-cash $11.75 billion deal, one of the biggest overseas acquisitions by an Indian pharmaceutical firm, as it sharpens its global expansion strategy.
Under the agreement announced last week of April, Sun Pharma will acquire all outstanding shares of Organon for $14 per share in cash. The boards of both companies have cleared the transaction, which is expected to be completed in the first quarter of 2027, subject to regulatory and shareholder approvals.
The acquisition is expected to significantly widen Sun Pharma’s presence in international markets and move the company beyond its traditional generics business. Through the deal, the Indian drugmaker will gain access to Organon’s strong portfolio in women’s health, biosimilars and established medicines, with products sold across more than 140 countries.
The move gives Sun Pharma a stronger entry into the fast-growing biosimilars segment, which includes lower-cost versions of complex biological drugs. Industry observers said the acquisition reflects the company’s strategic shift towards higher-growth and specialised healthcare segments.
The transaction is also expected to strengthen Sun Pharma’s global revenue base and improve its long-term growth outlook. Analysts view the deal as a major step in the company’s effort to scale up internationally and reduce dependence on the generics market.
With this acquisition, Sun Pharma signals a broader ambition to emerge as a stronger global player in specialised pharmaceuticals, women’s healthcare and advanced drug segments.